Tango Therapeutics Inc. (TNGX) PT Raised to $18 at Jefferies Mar 5, 2026 04:46PM
Stifel Reiterates Buy Rating on Tango Therapeutics Inc. (TNGX) following Q4 results Mar 5, 2026 10:30AM
Tango Therapeutics, Inc. (TNGX) Tops Q4 EPS by 3c Mar 5, 2026 07:37AM
Weakness in this biopharma stock is a buying opportunity: Leerink Feb 27, 2026 05:30PM
Stifel Earlier Defended Tango Therapeutics Inc. (TNGX) Amid 12pct Decline Feb 26, 2026 01:25PM


Feb 23, 2026 04:02AM Mizuho Starts Tango Therapeutics Inc. (TNGX) at Outperform
Jan 12, 2026 08:45AM Tango Therapeutics (TNGX) Reiterated at Buy by Stifel After Pipeline Updates
Dec 22, 2025 07:06AM Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
Dec 3, 2025 04:06PM Stifel Starts Tango Therapeutics Inc. (TNGX) at Buy
Nov 21, 2025 08:37AM Tango Therapeutics, Inc (TNGX) files mixed shelf
Nov 21, 2025 08:34AM Tango Therapeutics, Inc (TNGX) files for 1.73M share offering by selling stockholders
Nov 4, 2025 09:04AM Tango Therapeutics, Inc. (TNGX) Misses Q3 EPS by 7c
Oct 27, 2025 06:44AM Tango Therapeutics Inc.'s (TNGX) Vopimetostat Efficacy Impressive: Cantor Fitzgerald
Oct 24, 2025 06:42AM Tango Therapeutics Inc. (TNGX) PT Raised to $12 at Guggenheim
Oct 23, 2025 11:39AM Tango Therapeutics Inc. (TNGX) PT Raised to $15 at Wedbush
Oct 23, 2025 07:25AM Tango Therapeutics raises $225 million in stock offering
Aug 25, 2025 04:09PM Tango Therapeutics chief legal officer resigns to pursue new opportunity
Aug 19, 2025 06:18AM Piper Sandler Starts Tango Therapeutics Inc. (TNGX) at Overweight
Aug 5, 2025 07:04AM Tango Therapeutics, Inc. (TNGX) Reports In-Line Q2 EPS
Jun 30, 2025 06:52AM H.C. Wainwright Reiterates Buy Rating on Tango Therapeutics Inc. (TNGX)
Jun 27, 2025 07:03AM Tango Therapeutics (TNGX) Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lun
May 21, 2025 07:01AM Tango Therapeutics, Inc (TNGX) Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
May 12, 2025 07:04AM Tango Therapeutics, Inc. (TNGX) Reports In-Line Q1 EPS
Apr 14, 2025 06:53AM H.C. Wainwright Reiterates Buy Rating on Tango Therapeutics Inc. (TNGX)
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Nov 6, 2024 07:15AM Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c
Nov 6, 2024 07:11AM Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c
Nov 6, 2024 07:02AM Tango Therapeutics, Inc (TNGX) Reports Positive TNG462 Clinical Data, Provides Update on PRMT5 Development Program
Oct 28, 2024 07:29AM H.C. Wainwright Reiterates Buy Rating on Tango Therapeutics Inc. (TNGX)
Oct 15, 2024 05:59AM Leerink Partners Reiterates Outperform Rating on Tango Therapeutics Inc. (TNGX)
Sep 17, 2024 07:20AM Piper Sandler Reiterates Overweight Rating on Tango Therapeutics Inc. (TNGX)
Sep 10, 2024 06:42AM H.C. Wainwright Reiterates Buy Rating on Tango Therapeutics Inc. (TNGX)
Sep 9, 2024 07:37AM Piper Sandler Reiterates Overweight Rating on Tango Therapeutics Inc. (TNGX)
Jul 17, 2024 02:21AM Jefferies Starts Tango Therapeutics Inc. (TNGX) at Buy